Food and Drug Administration (FDA) has approved PD-1/PD-L1 IHC, TMB, proficient mismatch repair (pMMR) proteins, deficient mismatch repair (dMMR), and MSI-high (MSI-H) for specific tumor types and drugs as companion or complementary diagnostics (2). The gene discussed is CD274; the disease is neoplasm.